skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Management of venous thromboembolism in patients with cancer: role of dalteparin

Review

(2394) Views  (416) Full article downloads

Authors: Lori-Ann Linkins

Published Date May 2008 Volume 2008:4(2) Pages 279 - 287
DOI: http://dx.doi.org/10.2147/VHRM.S2132

Lori-Ann Linkins

Department of Hematology and Thrombosis, McMaster University, Hamilton, Ontario, Canada

Abstract: Cancer is a major risk factor for the development of venous thromboembolism (VTE). Conventional anticoagulant therapy with a vitamin K antagonist is more problematic in cancer patients due to an increased risk of recurrent VTE, and an increased risk of anticoagulant-related bleeding. In recent years, there has been a shift toward treating cancer patients with VTE with extended duration dalteparin. Dalteparin, a low-molecular-weight heparin, has been shown to be more effective, and as safe as conventional anticoagulant therapy, in cancer patients with VTE. This paper will (a) review the relationship between cancer and VTE, and (b) provide an overview of the role of dalteparin in the management of VTE in patients with cancer.

Keywords: dalteparin, cancer, venous thromboembolism








Readers of this article also read:

The efficacy of somatostatin analogues in the treatment of diabetic retinopathy and thyroid eye disease
Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Antihypertensive therapy among newly treated patients: An analysis of adherence and cost of treatment over years
Impact of nutrition on serum percentage in heifers
Fitting the pieces together: current research on the genetic basis of attention-deficit/hyperactivity disorder (ADHD)
Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens
Corrigendum - Functional mobility and balance in community dwelling elderly submitted to multisensory versus strength exercises
Editorial
Erratum
Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University